Sigachi Industries Limited (NSE:SIGACHI)
India · Delayed Price · Currency is INR 22.37
-0.64 (-2.78%)
Jan 23, 2026, 3:29 PM IST
Sigachi Industries Revenue
Sigachi Industries had revenue of 1.13B INR in the quarter ending September 30, 2025, a decrease of -9.55%. This brings the company's revenue in the last twelve months to 5.09B, up 15.36% year-over-year. In the fiscal year ending March 31, 2025, Sigachi Industries had annual revenue of 5.00B with 23.81% growth.
Revenue (ttm)
5.09B
Revenue Growth
+15.36%
P/S Ratio
1.73
Revenue / Employee
3.37M
Employees
1,507
Market Cap
8.79B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 5.00B | 962.25M | 23.81% |
| Mar 31, 2024 | 4.04B | 1.02B | 33.79% |
| Mar 31, 2023 | 3.02B | 517.55M | 20.68% |
| Mar 31, 2022 | 2.50B | 544.85M | 27.83% |
| Mar 31, 2021 | 1.96B | 530.96M | 37.21% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 17.25B |
| Nectar Lifesciences | 16.70B |
| Solara Active Pharma Sciences | 12.06B |
| Windlas Biotech | 8.30B |
| Orchid Pharma | 8.21B |
| Ind-Swift Laboratories | 5.72B |
| Beta Drugs | 3.86B |
| Jagsonpal Pharmaceuticals | 2.85B |